In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ocular Therapeutix brings in $14mm through its Series D round; adds money

Executive Summary

Ocular Therapeutix Inc. (focused on the delivery of ophthalmic drugs using hydrogel technology) has raised $14mm through its Series D venture round. New investor Ascension Health Ventures led and was joined by current shareholders including Polaris Ventures, SV Life Sciences, and Versant Ventures. The company will use the proceeds for Phase II trials of its sustained drug delivery system--a moxifloxacin-loaded punctum plug--later this year to reinforce safety and test efficacy, and to study the punctum plugs in the future for glaucoma, dry eye, and allergies.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies